TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06498128
Drug: Non-orexin receptor antagonist medications for insomnia
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing and treatment duration of non-orexin receptor antagonist medications for insomnia as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
Study: NCT06446479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06471868
Drug: IY-HCR21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betanechol 50mg
Study: NCT06343493
Drug: Normal saline heated up to 50 °C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline heated up to 50 °C used for irrigation
Study: NCT04854460
Drug: Revemact
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 6 mg Ivermecin
Study: NCT05498857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia
Study: NCT05216965
Drug: 9MW2821
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
Study: NCT06081907
Drug: IBI363
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI363 is based on the 3+3 model with a dose of 1 mg/kg Q3W. IBI325, 20 mg/kg Q3W.
Study: NCT06081907
Drug: IBI363
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI363 is based on the 3+3 model with a dose of 1.5 mg/kg Q3W. IBI325, 20 mg/kg Q3W.
Study: NCT06081907
Drug: IBI363
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI363 is based on the 3+3 model with a dose of 600 μg/kg Q2W. Lenvatinib, 8mg QD.
Study: NCT06081907
Drug: IBI363
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI363 is based on the 3+3 model with a dose of 1000 μg/kg Q2W. Lenvatinib, 8mg QD.
Study: NCT06081907
Drug: IBI363
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).
Study: NCT00002220
Drug: Levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06545474
Drug: SSRI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive 4 weeks SSRI treatment with escitalopram (10mg/day) as standard drug.
Study: NCT05454098
Drug: Clifutinib with fed state
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Clifutinib with food
Study: NCT05454098
Drug: Clifutinib with fasted state
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Clifutinib without food
Study: NCT06561841
Drug: HSK39297
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK39297 tablets for 24 weeks
Study: NCT05815303
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 po bid on day 1 to 14, every 21 day
Study: NCT05824585
Drug: DZD8586
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
Study: NCT06500091
Drug: TQB2916 injection + doxorubicin hydrochloride for injection
Normalized name: doxorubicin hydrochloride Injection
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TQB2916 is a humanized immune gamma globulins 2 (IgG2) monoclonal antibody targeting CD40.~The mechanism of action of doxorubicin is mainly to destroy the DNA structure of tumor cells, thereby killing malignant tumors. It interferes with the DNA synthesis process of cancer cells by targeting DNA and inhibiting enzymes in DNA replication and repair. In addition, doxorubicin can also trigger cross-link breaks in DNA, leading to apoptosis of cancer cells.
Study: NCT05190068
Drug: HMPL-760
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.
Study: NCT06562114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05853185
Drug: Pro Root MTA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive the pulpotomy with Pro Root MTA®.
Study: NCT01163383
Drug: 131 I-MIBG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131-I-MIBG will be infused intravenously over 60-90 minutes once per course. The dose will be determined by the treating physician.
Study: NCT05853185
Drug: EBRRM®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive the pulpotomy with Endo Sequence Bioceramic Root Repair (EBRRM)®.
Study: NCT04019015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution
Study: NCT04914351
Drug: HY-0102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
Study: NCT05337228
Drug: IN-C006 Peri inj.
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN-C006 peri inj. will be injected continuously for 3 days.
Study: NCT05337228
Drug: RPN301
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPN301 will be injected continuously for 3 days.
Study: NCT06415903
Drug: TQB3117 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3117 is a protein inhibitor.
Study: NCT06108479
Drug: DF6215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (cytokine) targeting effector cells.
Study: NCT04784416
Drug: 18F-MK-6240
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET tracer to be injected prior to PET imaging session, which will occur during baseline assessments
Study: NCT06268015
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 IV every 2 weeks
Study: NCT06268015
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 IV bolus + 2,400 mg/m2 IV (over 46 hours) every 2 weeks
Study: NCT04866108
Drug: fruquintinib plus capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral fruquintinib plus capecitabine
Study: NCT06487702
Drug: fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib administration for 2 weeks followed by 1-week break~Candonilimab：10 mg/kg，D1，Q3W；~Tegafur，Gimeracil and Oteracil Potassium：30mg BID for body surface area \< 1.25 m2; 40mg BID for body surface area of 1.25-1.5 m2; and 50mg BID for body surface area \>1.5 m2; D1-14, q3w
Study: NCT05459571
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT06771622
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 PO BID on Days 1-14, Cycled every 21 days
Study: NCT06771622
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 IV on Day 1 every 2 weeks
Study: NCT06041217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of placebo once-weekly at escalation doses manner as semaglutide every fourth week until maintenance dose of placebo matched to 2.4 mg is reached.
Study: NCT05163808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05826600
Drug: OMX-0407
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation, Dose expansion
Study: NCT05059600
Drug: ZULRESSO®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ZULRESSO®.
Study: NCT05187481
Drug: Placebo granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
Study: NCT06419140
Drug: Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational counseling to perform nutritional, psychological, and exercise inventions
Study: NCT06374823
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are randomized to normal saline group will be receiving Sodium Chloride injection for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.
Study: NCT03939364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05219864
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study: NCT06507813
Drug: ADC189 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients weigh between 20 to 80 kilograms, given 45 mg ADC189 tablets once; patients weigh over 80 kilograms, given 90 mg ADC189 tablets once.
Study: NCT06507813
Drug: Placebo of ADC189 tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients weigh between 20 to 80 kilograms, given 1 tablet of placebo once; patients weigh over 80 kilograms, given 2 tablets of placebo once.
Study: NCT06507813
Drug: ADC189 granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patient 5-11 years old, patients weigh between 20 to 80 kilograms, given 45 mg ADC189 granules once; patients weigh over 80 kilograms, given 90 mg ADC189 granules once.~For patient 2-4 years old, patients \<10kg, given 15mg ADC189 granules once. 10kg \~ \<15kg, given 25mg ADC189 granules once. 15kg \~\<20 kg, given 35mg ADC189 granules once. 20kg \~ \<80kg, given 45mg ADC189 granules once.
Study: NCT06507813
Drug: Placebo of ADC189 granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo. Given once only.
Study: NCT06037330
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil was injected intravenously, and the target CPOT score was \<2, and the target RASS score was -2 \~ 1. 0.1mg of sufentanil was diluted into 50 mL solution, the loading dose was 0.2-0.5μg/kg, the maintenance dose was 0.2-0.3μg/kg/h, and the CPOT score was \<2 points
Study: NCT06596018
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue to follow the original chemotherapy regimen（anthracycline and/or taxane based regimens）
Study: NCT05546762
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleural irrigation with normal saline
Study: NCT06373627
Drug: Conventional medications used for sedation-analgesia
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEOPA + intravenous ketamine (0.5 mg/kg) + intraveinous midazolam (50µg/kg)
Study: NCT06373627
Drug: Medications used in addition to hypnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEOPA + intravenous ketamine (0.3 mg/kg)
Study: NCT05283720
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV; Injection
Study: NCT05283720
Drug: Doxorubicin Hydrochloride [HCl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV; Injection
Study: NCT05171387
Drug: Androgen deprivation therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) is a treatment that commonly used to lower the amount of hormones called androgens in the body.
Study: NCT04335461
Drug: Regional Anesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marcaine 0.25% will be administered for the two experimental arms, as described in above protocol.
Study: NCT06653634
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gradual withdrawal of the medication
Study: NCT06653634
Drug: TNF Inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual withdrawal of the medication
Study: NCT04836494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BBP-671
Study: NCT06152796
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non steroidal anti_inflammatory drug
Study: NCT06372964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally, once daily.
Study: NCT04834531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsule is filled with amylodextrin made with food colour and flavor，with the similar appearance, smell and flavor with Zhuli Capsule. It is oral used, 2 capsules for once, three times a day, for 7 days.
Study: NCT05087069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline intravenous infusion
Study: NCT05418504
Drug: Dental anesthesia
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dental anesthesia, used to do any dental procedure
Study: NCT05336071
Drug: INS068 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.
Study: NCT05336071
Drug: INS068 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.
Study: NCT05144360
Drug: Atenas
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATENAS 1 coated tablet, once a day EMPAGLIFLOZIN PLACEBO Empagliflozin placebo 1 coated tablet, once a day TELMISARTAN + AMLODIPINE PLACEBO Telmisartan + amlodipine 1 coated tablet, once a day
Study: NCT05144360
Drug: Atenas placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: EMPAGLIFLOZIN Empagliflozin 25 mg 1 coated tablet, once a day. Drug: TELMISARTAN Telmisartan + Amlodipine 40 + 5/80 +5 mg 1 coated tablet, once a day ATENAS PLACEBO Atenas placebo 1 coated tablet, once a day
Study: NCT06156085
Drug: Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg + amoxicillin 1000 mg b.i.d. AC for 7 days, followed by the same PPI + clarithromycin 500 mg + metronidazole 500 mg b.i.d. AC for 7 days
Study: NCT04332588
Drug: [18F]FMISO PET/MRI imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]FMISO PET/MRI imaging
Study: NCT04854681
Drug: TQB2928 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weekly IV infusions (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
Study: NCT05021991
Drug: 100 mg PRAX-944
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment with titration
Study: NCT05021991
Drug: 60 mg PRAX-944
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment with titration
Study: NCT05021991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment
Study: NCT05021991
Drug: Flexibly dosed 20 mg to 100 mg PRAX-944
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment
Study: NCT04931004
Drug: Mouthwash Product
Normalized name: Mouthwash Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially over-the-counter Colgate mouthwashes will be administered according to standard package instructions. Viral load will be measured prior to and after mouth rinse using serial face mask and saliva samples.
Study: NCT03971110
Drug: Zoladex and Casodex
Approvals — FDA: no, EMA: no, PMDA: no
Description: The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
Study: NCT05105607
Drug: D-4517.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection
Study: NCT04602754
Drug: ROSUVASTATIN CALCIUM
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20 mg coated tablet.
Study: NCT05216562
Drug: COVID-19 Standard Treatment
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific drugs considered standard treatment for COVID-10 by each location may vary
Study: NCT04460235
Drug: Prevenar13 Pneumo-23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination according national guidelines
Study: NCT05039359
Drug: FlecIH-103
Approvals — FDA: no, EMA: no, PMDA: no
Description: flecainide acetate inhalation solution
Study: NCT04991766
Drug: [¹⁴C]-LY3484356
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04991766
Drug: LY3484356
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04991766
Drug: [¹⁴C]-LY3484356 (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT05269394
Drug: E2814
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously in a blinded fashion
Study: NCT05269394
Drug: Matching Placebo (E2814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously in a blinded fashion.
Study: NCT06095765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of matching placebo once daily
Study: NCT06222125
Drug: HB0025
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB0025 IV every 2 weeks (q2w)
Study: NCT03315832
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
Study: NCT06282120
Drug: Irinotecan Hydrochloride Liposome Injection ；Fluorouracil ；Leucovorin；immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended dose and regimen of Irinotecan Hydrochloride Liposome Injection is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 3 weeks.It can be combined or partially combined immunotherapy.
Study: NCT05838391
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As part of the subjects' treatment, 825 mg/meters squared per day, divided into 2 daily doses, will be taken on days of radiotherapy. Capecitabine or 5-FU will be administered per the physician's discretion.
Study: NCT01207622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05166304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive the standard therapy (methotrexate) plus placebo tablets
Study: NCT05370807
Drug: Triplet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib in combination with BRAF- / MEK- inhibitors
Study: NCT06238388
Drug: HSK21542 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous dose of 0.8 μg/kg HSK21542 in boluses after D1 dialysis completed.
Study: NCT05949008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be provided as 1000 mg capsules
Study: NCT06194565
Drug: 99mTc-ABH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive an intravenous injection of 99mTc-ABH2, and undergo a SPECT/CT scan within specified time.
Study: NCT05638360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patch contains 13g starch and 10c.c. water.
Study: NCT06128447
Drug: ZP5-9676 600 mg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, chewable tablet formulation of flubendazole
Study: NCT06128447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04613960
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment
Study: NCT04810390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution
Study: NCT05490563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sodium chloride injection, 0.9%, USP)
Study: NCT04673422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
Study: NCT04994535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injection
Study: NCT05785715
Drug: NX-13 250mg
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX-13 250mg tablet, plus 2 placebo tablets
Study: NCT05785715
Drug: NX-13 750mg
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX-13 250mg tablets times 3 to equal 750mg
Study: NCT06560593
Drug: NTQ5082
Approvals — FDA: no, EMA: no, PMDA: no
Description: single ascending dose, randomized, double-blind study，with 8 dose groups preset. The first cohort will be the sentinel group, consisted of 2 subjects receiving NTQ5082 capsules. The remaining cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
Study: NCT06560593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple ascending dose, randomized, double-blind study，with 3 dose groups preset. All cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
Study: NCT04150042
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ethanol (to be given in conjunction with the other listed drugs).
Study: NCT06612840
Drug: GNC-077
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT02630121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proportion of the subjects with 50% reduction in AHI.
Study: NCT05466877
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG-K10 Humanized Monoclonal Antibody Injection
Study: NCT05251727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight based dose of reconstituted treatment
Study: NCT06790589
Drug: Levothyroxine Oral Tablet [Synthroid]
Normalized name: levothyroxine Oral Tablet [Synthroid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Round, colour coded, scored tablet debossed with SYNTHROID on one side and potency on the other side.